Compare Abbott Laboratories (ABT) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Kinder Morgan Inc — how do they compare? Abbott Laboratories trades at $95.59 (market cap $166.94B), while Kinder Morgan Inc trades at $32.43 (market cap $72.28B). The key difference: Abbott Laboratories is far larger — about 2.3× Kinder Morgan Inc's market cap, and Kinder Morgan Inc pays the higher dividend (3.62%). Which is the better fit depends on your goals.
| ABT | KMI | |
|---|---|---|
Market Cap | $166.94B | $72.28B |
Sector | Health | Energy |
52-Week High | $136.62 | $34.31 |
52-Week Low | $82.57 | $25.84 |
Enterprise Value | $193.69B | $104.16B |
Dividend Yield | 2.63% | 3.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
KMI trades at $32.49, up 1.34% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.48, and maintains a solid dividend of $0.30 per share. Revenue grew to $16.94B in 2025, with net income reaching $3.06B, reflecting an 18.04% margin. Analyst consensus is mixed, with 47% buy ratings and 50% hold.
KMI's outlook is supported by stable cash flows from fee-based contracts and a $10.1B project backlog focused on natural gas infrastructure. Key risks include high debt levels and exposure to energy market volatility. The stock offers income potential with a near 4% yield, but investors should monitor execution on growth projects and commodity price trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
